Progressive supranuclear palsy
Drug research and approvals for progressive supranuclear palsy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 34 studies of progressive supranuclear palsy are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 0 approved and 20 open orphan designations naming it.
- Recruiting worldwide: 34
- Trials authorized in Canada: 3
- FDA orphan approvals: 0
- EU medicines: 0
- Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual TrialNCT07863180 · Phase 1 / Phase 2 · Prabesh Kanel · starts Oct 1, 2026
- Wellness in PSP and CBDNCT07844655 · Not applicable · Silke Cresswell · starts Apr 10, 2026
- Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)NCT07805967 · Not reported · Second Affiliated Hospital of Soochow University · starts Nov 12, 2025
- Biofluid Research on Age-Related or Inherited NeurodegenerationNCT07798700 · Not reported · University of Pennsylvania · starts Dec 12, 2025
- Individualized Transcranial Magnetic Stimulation in Parkinsonian DisordersNCT07570212 · Not applicable · Peking University First Hospital · starts Dec 22, 2025
- Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic DisordersNCT07509125 · Not applicable · Universitaire Ziekenhuizen KU Leuven · starts Feb 13, 2026
- A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear PalsyNCT07498426 · Phase 3 · Novartis Pharmaceuticals · starts Jun 3, 2026
- Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital…NCT07392411 · Not reported · Beijing Tiantan Hospital · starts Jul 25, 2023
- tDCS as Treatment for Motor FunctionNCT07291687 · Not applicable · Baycrest · starts Oct 30, 2025
Phase 3 3
- RasagilineMonoamine oxidase B inhibitor
- RivastigmineCholinesterases; ACHE & BCHE inhibitor
- RiluzoleSodium channel alpha subunit blocker
Phase 2 7
- TilavonemabMicrotubule-associated protein tau inhibitor
- UbidecarenoneSupplement
- GosuranemabMicrotubule-associated protein tau inhibitor
- Tertomotide
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- DonepezilAcetylcholinesterase inhibitor
- DavunetideTubulin stabiliser
Phase 1 or earlier 5
- BepranemabMicrotubule-associated protein tau inhibitor
- Lithium carbonateInositol-1(or 4)-monophosphatase 1 inhibitor
- Salsalate
- Lipoic acid, alpha
- Tolfenamic acid
How its trials ended
139 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 16 whose ending is known, 19% met their primary endpoint, 13% missed it and 69% stopped early.
- Completed, result not reported6144%
- Ongoing4532%
- Status unknown1712%
- Stopped: other or unclear54%
- Met its primary endpoint32%
- Stopped: lack of efficacy32%
- Stopped: funding32%
- Missed its primary endpoint21%
| Sep 30, 2020 | A randomized, participant, investigator and sponsor blinded, placebo- controlled study to evaluate the safety, tolerability and pharmacokinetics of multiple…NIO752 | Novartis Pharmaceuticals | Closed |
| May 4, 2017 | A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of intravenously administered BMS-986168 in…BMS-986168 | Bristol-Myers Squibb | Closed |
| Apr 21, 2017 | Four repeat tauopathy neuroimaging initiative[C-11]PIB / 18F AV-1451 (18F T807) | Pet Centre Centre for Addiction and Mental Health | Closed |
| Sep 21, 2026 | RifampinTreatment of progressive supranuclear palsy | Medilabo RFP, Inc. | Designated |
| Jul 23, 2026 | Sodium selenateTreatment of progressive supranuclear palsy | Monash University | Designated |
| Feb 4, 2026 | 2'-methoxyethyl antisense gapmer oligonucleotide against…Treatment of progressive supranuclear palsy | Novartis Pharmaceuticals Corporation | Designated |
| Jun 23, 2025 | A fully human IgG1k anti-programmed death ligand-1 (PD-L1)…Treatment of progressive supranuclear palsy (PSP) | ImmunoBrain Checkpoint Inc. | Designated |
| May 1, 2025 | TertomotideTreatment of progressive supranuclear palsy | GemVax & KAEL Co., Ltd. | Designated |
| Jan 5, 2021 | Izaflortaucipir (proposed INN)Diagnostic for the clinical management of progressive supranuclear palsy. | Lantheus Biosciences Ltd. | Designated |
| Dec 21, 2020 | FasudilTreatment of progressive supranuclear palsy | Woolsey Pharmaceuticals, Inc. | Designated |
| Jun 16, 2020 | Humanized IgG4 S228P monoclonal antibody targeting the cis…Treatment of Progressive supranuclear palsy | Pinteon Therapeutics Inc. | Designated |
| Jan 28, 2020 | Di-deuterated linoleic acidTreatment of Progressive Supranuclear Palsy | Retrotope, Inc. | Designated |
| Jul 10, 2018 | Competitive and reversible small molecule inhibitor of the…Treatment of progressive supranuclear palsy | Ferrer Internacional, S.A. | Designated |
| Nov 1, 2017 | 1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl…A diagnostic for the management of progressive supranuclear palsy | Aprinoia Therapeutics | Designated |
| Sep 5, 2017 | Recombinant humanized IgG4P monoclonal antibody with…Treatment of progressive supranuclear palsy (PSP) | UCB, Inc. | Designated |
| Mar 20, 2017 | N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H…Treatment of progressive supranuclear palsy | Alzprotect sas | Designated |
| Jul 13, 2016 | Tolfenamic acidTreatment of progressive supranuclear palsy | Nasser H. Zawia | Designated |
| May 13, 2015 | Anti-eTau Humanized IgG4 Monoclonal AntibodyTreatment of Progressive Supranuclear Palsy | Biogen, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA